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Both amyloid light chain (AL) amyloidosis and transthyretin (TTR) 
amyloidosis are now expanding indications for heart transplantation (HTx)
In the past, AL amyloid, in particular, had been a contraindication to HTx given 
its suboptimal control, systemic nature & progression to other organs, pre-
malignant character, recurrence in allograft/transplanted organ, and the 
increased risk for mortality. 
Advanced ACM carries a poor prognosis!
Standard heart failure therapies have limited utility & can be harmful: 
including Beta-blockers, ACEIs, ARBs, Digoxin
Left Ventricular Assist Devices (LVADs) have had only isolated successes
- Use of these is often limited by RV dysfunction -> restrictive CM
Modern treatments including proteasome inhibitors (reversible, such as 
Bortezomib, or irreversible) combined with traditional chemotherapy 
drugs (such as melphalan or dexamethasone) have allowed amyloid 
patients to increasingly receive heart transplants
- Normalization of free-light chains
- Rapid hematological improvement
- Used for amyloidosis relapse post-HTx
Methods
The Evolving Long-Term Outcome of Heart 
Transplantation in Amyloid Patients
Avish Jain, OMS-II, Sadia Dimbil, Ryan Levine, Michele Hamilton, and Jon A. Kabashigawa
Cedars-Sinai SMIDT Heart Institute, Los Angeles, CA
In past research, the 2-year survival rate of patients with cardiac amyloidosis 
is less than 20% without HTx compared to a survival rate of 60% after HTx
We sought to assess long-term post-transplant outcome in amyloid 
patients in the current era, using our patient population that underwent HTx
for cardiac amyloidosis at our single center. 
• Between 2010 and 2015, we assessed 45 Heart Transplant Pts:
• All Amyloid (n=27) -> broken up into AL (n=5), TTR wt
senile (n=10), TTR mutant (n=12)
• Non-Amyloid Restrictive Control (n=18)
• Endpoints included:
• Subsequent 3-year survival
• Subsequent 3-year freedom from CAV (as defined by stenosis 
≥ 30% by angiography) 
• Subsequent 3-year freedom from non-fatal major adverse 
cardiac events (NF-MACE: myocardial infarction, new 
congestive heart failure, percutaneous coronary intervention, 
implantable cardioverter defibrillator/pacemaker implant, 
stroke). 
• Subsequent 3-year freedom from any-treated rejection, acute 
cellular rejection, and antibody-mediated rejection
There was no significant difference between the All amyloid and restrictive 
non-amyloid patients with respect to 3-year survival and 3-year freedom 
from CAV, NF-MACE, and rejection.
Furthermore, there was no significant difference between the AL 
amyloid, TTR-wt, TTR-m, and restrictive non-amyloid patients with respect 
to 3-year survival and 3-year freedom from CAV, NF-MACE, and rejection.
Endomyocardial biopsies post-transplant did not show amyloid.
• In the current era, both AL & TTR amyloid patients have acceptable
mid-term outcome after HTx.
• Larger numbers & longer follow-ups are needed to confirm findings.
• Need to consider sociological & economical components to analyze 
the capability of patients to undergo & afford such extensive Tx.
• RNA TAFAMIDIS THERAPY, Doxycycline, Green Tea for now!





Mean Recipient Age, Years ± SD 66.6 ± 7.6 47.8 ± 14.3 <0.001
Mean Donor Age, Years ± SD 35.3 ± 11.7 34.2 ± 10.2 0.768
Body Mass Index, Mean ± SD 25.0 ± 3.9 24.7 ± 3.9 0.818
Female (%) 11.1% 61.1% <0.001
Previous Pregnancy in Females 
(%) 66.7% 45.5% 0.514
Ischemic Time, Mean Mins ± SD 144.1 ± 47.5 157.1 ± 59.2 0.420
Diabetes Mellitus (%) 22.2% 5.6% 0.130
Status 1 at Transplant (%) 74.1% 77.8% 0.777
Cytomegalovirus Mismatch (%) 22.2% 22.2% 1.000
Treated Hypertension (%) 43.5% 26.7% 0.293
Insertion of Mechanical 
Circulatory Support Device (%) 14.8% 5.6% 0.332
Prior Blood Transfusion (%) 30.4% 14.3% 0.266
Pre-Transplant PRA ≥ 10% (%) 25.9% 27.8% 0.890
Pre-Transplant Creatinine, 
Mean ± SD 1.5 ± 0.7 1.4 ± 1.0 0.629
